Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
IPO Year: 2018
Exchange: NASDAQ
Website: aridispharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/20/2021 | $11.00 → $19.00 | Buy | HC Wainwright & Co. |
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. Company update: The Company continues to diligently explore multiple paths to monetize its assets amidst a protracted challenging capital market and limited internal resources. During the second half of this year it has been in discussions with other pharmaceutical companies and investment firms on possible partnerships and investments in the clinical product candidates AR-301, AR-320, AR-501, and the APEX platform technology. The Company has substantially reduced its operational
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. The Company has been in sustained discussions with other pharmaceutical companies and investment firms on possible partnerships and investments on its clinical product candidates AR- 301, AR-320, AR-501, and the APEX platform technology. The principal goal for the discussions has been to build shareholder value by out-licensing or attracting capital investments to complete the final stages of product development. A summary of the status of the major programs is further highlight
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023. Third Quarter Highlights Received a grant award from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH), in collaboration with researchers at
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock (or pre-funded warrant) and accompanying warrant. Each warrant will have an exercise price per share of $0.20, will be exercisable immediately and will terminate on the five year ann
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients. Key agreements by the EMA were similar to those agreed by the US FDA, which include: Agreement on the design of the single confirmatory Phase 3 superiority
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically
ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessRail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' expe
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration's (FDA) Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). The FDA's agreement signifies that the AR-301 clinical program meets the requirements for a well-defined limited population with unmet medical need as designated in
HC Wainwright & Co. reiterated coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $11.00 previously
Northland Securities resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Roth Capital resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $18.00
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The
ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessRail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' expe
ORLANDO, FL / ACCESSWIRE / February 17, 2023 / RedChip Companies will air new interviews with Rail Vision Ltd. (NASDAQ:RVSN), Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), and Digital Ally, Inc. (NASDAQ:DGLY) on The RedChip Money Report® on Bloomberg TV, this Saturday, February 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Rail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessDigital Ally (NASDAQ:DGLY): https://digitalallyinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Mon
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webcast on Wednesday, January 25, at 4:15 p.m. ET to provide a business and pipeline update, including a discussion of topline data from the Company's Phase 3 study of AR-301 in adjunctive treatment of S. aureus ventilator associated pneumonia (VAP). The Company expects to publish topline data from AR-301 on January 25, prior to the call. A question-and-answer session will follow management's prepared remarks. Eve
The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pha
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022. Third Quarter Highlights Closed enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.Continued e
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022. Second Quarter Highlights Continued enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis remains on track to report top-line data from this study in 2H 2022.Continued enrollment in the Company's Phase 2a study of AR-501 targeting cy
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2022. First Quarter Highlights Continued enrollment in the Company's Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with funding support from the CF Foundation. The top-line data from this CF study is now expected in 2H 2022.Continued enrollment in the Company's Phase 3 study eval
Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights Continued enrollment in the Company's Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with the funding support from the C
8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
10-Q - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
10-Q - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)
25-NSE - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)
SC 13G - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)